Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis - A clinical evaluation
Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis - A clinical evaluation
复制标题
DOI：
10.1378/chest.124.1.186
复制
发表时间：
2003-07-01
期刊：
影响因子：
9.6
通讯作者：
van Velzen-Blad, H
中科院分区：
文献类型：
--
作者：
Grutters, JC;Fellrath, JM;van Velzen-Blad, H
目的：到目前为止，没有足够的证据推荐血清可溶性白介素-2受体（sIL-2R）测量作为结节病评估的常规检查。因此，我们评估了该试验的临床价值。设计：47例结节病患者均表现为活动性疾病，纳入研究。采用酶联免疫吸附法测定初始血清sIL-2R水平，并回顾性收集首发和随访时的临床资料。结果：所有患者的中位随访时间为44个月（范围6至100个月），38例患者的随访数据超过24个月。sIL-2R水平中位数为1068 U/mL（范围248 ~ 4410 U/mL，正常上限为710 U/mL）。血清sIL-2R水平与BAL中CD4+ T淋巴细胞数量呈正相关（rs = 0.53, p < 0.001）。由此可见，I期患者sIL-2R水平及CD4+ T淋巴细胞数量均高于III期患者（p < 0.05）。肺外疾病（ED）患者[不包括Lofgren综合征]的sIL-2R水平高于仅肺结节病患者（p = 0.001）。sIL-2R水平与治疗反应无相关性，sIL-2R水平与影像学进展和肺功能预后无相关性。结论：我们的数据表明，血清sIL-2R可作为结节病患者肺部疾病活动和ED的标志物。
Objectives: To date, insufficient evidence is available to recommend serum soluble interleukin-2 receptor (sIL-2R) measurement as a routine test in the assessment of sarcoidosis. Therefore, we evaluated the clinical value of this test.Design: Forty-seven patients with sarcoidosis, all presenting with active disease, were included in the study. Initial serum sIL-2R levels were determined by enzyme-linked immunosorbent assay, and clinical data at presentation and follow-up were collected retrospectively.Results: The median follow-up period of all patients was 44 months (range, 6 to 100 months), and 38 patients had follow-up data present over at least 24 months. The median sIL-2R level was 1,068 U/mL (range, 248 to 4,410 U/mL; upper limit of normal, 710 U/mL). A positive correlation was found between serum sIL-2R levels and the number of, CD4+ T lymphocytes in BAL (rs = 0.53, p < 0.001). In accordance with this result, both sIL-2R level and the number of CD4+ T lymphocytes were elevated in stage I compared to stage III disease (p < 0.05). Patients with extrapulmonary disease (ED) [excluding Lofgren's syndrome] showed higher sIL-2R levels than those presenting with only pulmonary sarcoidosis (p = 0.001). No relation was found between sIL-2R level and response to treatment, and there was no association between sIL-2R levels and radiographic evolution and lung function outcome.Conclusions: Our data suggest a role for serum sIL-2R as marker of pulmonary disease activity and ED in patients with sarcoidosis.